ELUT Earnings Soar on Debt Cut and Divestiture Shares Still Tumble

Elutia (ELUT) reported fiscal 2025 Q4 earnings on March 13, 2026, with revenue rising 16.2% year-over-year to $3.27 million. The company delivered a stunning turnaround, posting a $70.79 million net income and $1.65 EPS—both reversing a 2024 Q4 net loss of $9.06 million and $0.26 EPS. Despite beating expectations, shares fell 6.09% on the day, though the stock gained 13.67% month-to-date. Strategic moves, including a $88 million divestiture and improved gross margins, underscored operational progress.

Revenue

The total revenue of Elutia increased by 16.2% to $3.27 million in 2025 Q4, up from $2.82 million in 2024 Q4.

Earnings/Net Income

Elutia returned to profitability with EPS of $1.65 in 2025 Q4, reversing from a loss of $0.26 per share in 2024 Q4 (742.8% positive change). Meanwhile, the company achieved a remarkable turnaround with net income of $70.79 million in 2025 Q4, representing an 881.3% positive swing from the net loss of $-9.06 million in 2024 Q4. The Company has sustained losses for 6 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. Elutia’s $1.65 EPS marked a 742.8% rebound from a 2024 Q4 loss, signaling a strong turnaround.

Price Action

The stock price of Elutia has dropped 6.09% during the latest trading day, has edged down 0.92% during the most recent full trading week, and has jumped 13.67% month-to-date.

Post-Earnings Price Action Review

The strategy of buying Elutia (ELUT) shares after a quarterly revenue drop on the financial report release date and holding for 30 days resulted in a -57.61% return over the past three years. The strategy underperformed the benchmark significantly, with an excess return of -103.58% and a CAGR of -19.59%. The strategy also exhibited high volatility and risk, with a maximum drawdown of 88.01% and a Sharpe ratio of -0.18.

CEO Commentary

CEO C. Mills on Strategic Turnaround

Elutia’s CEO highlighted the company’s “transformative progress” in the 2025 Q4 call, emphasizing the elimination of $28 million in debt and the $88 million BioEnvelope divestiture as pivotal to balance sheet strength. He noted, “Our direct distribution model has driven a 10.3% gross margin improvement, enabling sustainable profitability.” While acknowledging the 6-year quarterly losses, Mills expressed cautious optimism, stating, “We remain focused on disciplined R&D investments and expanding our commercial footprint in high-margin markets.”

Guidance

Forward-Looking Targets and Expectations

Elutia expects to achieve FDA clearance for its NXT-41X product by H1 2027, targeting a $1.5 billion breast reconstruction market. The company guides to maintaining gross margins above 65% through 2026 and aims to reduce net debt by 30% year-over-year. Qualitatively, leadership emphasized prioritizing “strategic partnerships and operational efficiency” to sustain profitability.

Additional News

Elutia’s recent $88 million BioEnvelope divestiture to Boston Scientific marked its largest non-earnings-related transaction in 2025. The company also announced a $10 million share repurchase program, signaling confidence in its improved liquidity. Additionally, the FDA clearance timeline for NXT-41X, expected by mid-2027, has sparked investor speculation about market expansion. These moves follow a 60% one-year stock decline, reflecting a strategic shift toward capital preservation and high-impact product launches.